Cover Image
市場調查報告書

幼年型慢性關節炎:開發中產品分析

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363116
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
幼年型慢性關節炎:開發中產品分析 Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 72 Pages
簡介

本報告提供幼年型慢性關節炎治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

幼年型慢性關節炎概要

治療藥的開發

  • 開發中產品的概要

幼年型慢性關節炎:企業開發中的治療藥

幼年型慢性關節炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

幼年型慢性關節炎:企業開發中的產品

幼年型慢性關節炎治療藥的開發企業

  • Alteogen Inc.
  • Bristol-Myers Squibb Company
  • Epirus Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Oncobiologics, Inc.

幼年型慢性關節炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

幼年型慢性關節炎:暫停中的計劃

幼年型慢性關節炎:中止開發的產品

幼年型慢性關節炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8199IDB

Summary

Global Markets Direct's, 'Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016', provides an overview of the Systemic Idiopathic Juvenile Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Systemic Idiopathic Juvenile Arthritis
  • The report reviews pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Systemic Idiopathic Juvenile Arthritis therapeutics and enlists all their major and minor projects
  • The report assesses Systemic Idiopathic Juvenile Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Systemic Idiopathic Juvenile Arthritis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Systemic Idiopathic Juvenile Arthritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Systemic Idiopathic Juvenile Arthritis Overview
  • Therapeutics Development
    • Pipeline Products for Systemic Idiopathic Juvenile Arthritis - Overview
  • Systemic Idiopathic Juvenile Arthritis - Therapeutics under Development by Companies
  • Systemic Idiopathic Juvenile Arthritis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Systemic Idiopathic Juvenile Arthritis - Products under Development by Companies
  • Systemic Idiopathic Juvenile Arthritis - Companies Involved in Therapeutics Development
    • Alteogen Inc.
    • Bristol-Myers Squibb Company
    • Epirus Biopharmaceuticals, Inc.
    • Johnson & Johnson
    • Momenta Pharmaceuticals, Inc.
    • Mycenax Biotech Inc.
    • Novartis AG
    • Oncobiologics, Inc.
  • Systemic Idiopathic Juvenile Arthritis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abatacept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abatacept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abatacept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • canakinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • golimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Systemic Idiopathic Juvenile Arthritis - Dormant Projects
  • Systemic Idiopathic Juvenile Arthritis - Discontinued Products
  • Systemic Idiopathic Juvenile Arthritis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
      • Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris
      • May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis
      • Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials
      • Nov 08, 2012: Bristol-Myers Squibb To Present New Investigational Data On Orencia At 2012 American College Of Rheumatology Annual Scientific Meeting
      • Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012
      • Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Alteogen Inc., H1 2016
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Johnson & Johnson, H1 2016
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Mycenax Biotech Inc., H1 2016
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Novartis AG, H1 2016
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Oncobiologics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Systemic Idiopathic Juvenile Arthritis - Dormant Projects, H1 2016
  • Systemic Idiopathic Juvenile Arthritis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top